• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature.

作者信息

Ito Kenichi, Nishiyama Risa, Hirano Kazuhiko, Yamada Kazuaki, Sekiguchi Naohiro

机构信息

Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

出版信息

Blood Res. 2019 Sep;54(3):236-240. doi: 10.5045/br.2019.54.3.236. Epub 2019 Sep 25.

DOI:10.5045/br.2019.54.3.236
PMID:31730686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6779941/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ce/6779941/741deda26642/br-54-236-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ce/6779941/9aaf47e97e0a/br-54-236-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ce/6779941/741deda26642/br-54-236-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ce/6779941/9aaf47e97e0a/br-54-236-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25ce/6779941/741deda26642/br-54-236-g002.jpg

相似文献

1
Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature.含硼替佐米方案成功治疗非IgM淋巴浆细胞淋巴瘤：病例报告及文献综述
Blood Res. 2019 Sep;54(3):236-240. doi: 10.5045/br.2019.54.3.236. Epub 2019 Sep 25.
2
Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenström's macroglobulinemia with bortezomib.硼替佐米成功治疗MYD88 L265P突变阴性的华氏巨球蛋白血症中的难治性冷凝集素血症
Int J Hematol. 2015 Aug;102(2):238-43. doi: 10.1007/s12185-015-1775-3. Epub 2015 Mar 21.
3
Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.硼替佐米和来那度胺联合治疗难治性浆母细胞淋巴瘤。
Oncol Res Treat. 2020;43(3):112-116. doi: 10.1159/000504608. Epub 2019 Dec 16.
4
Primary CNS lymphoplasmacytic lymphoma: a case report and review of literature.原发性中枢神经系统淋巴浆细胞淋巴瘤：一例报告并文献复习
Hematol Oncol Stem Cell Ther. 2013 Jun;6(2):76-8. doi: 10.1016/j.hemonc.2013.06.002. Epub 2013 Jun 19.
5
[The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].[淋巴浆细胞淋巴瘤/华氏巨球蛋白血症的病理学及遗传背景]
Magy Onkol. 2017 Mar 8;61(1):6-11. Epub 2016 Nov 28.
6
[Waldenström macroglobulinemia].[华氏巨球蛋白血症]
Orv Hetil. 2013 Dec 1;154(50):1970-4. doi: 10.1556/OH.2013.29776.
7
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis.硼替佐米在新诊断弥漫性大 B 细胞淋巴瘤中的作用：一项荟萃分析。
Ann Hematol. 2018 Nov;97(11):2137-2144. doi: 10.1007/s00277-018-3435-1. Epub 2018 Jul 19.
8
Concomitant lymphoplasmacytic lymphoma and plasma cell myeloma, a diagnostic challenge.伴发淋巴浆细胞淋巴瘤和浆细胞骨髓瘤：一项诊断挑战
Am J Blood Res. 2017 Apr 15;7(2):10-17. eCollection 2017.
9
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.不伴有 IgM 单克隆蛋白的淋巴浆细胞淋巴瘤的临床和分子特征：伦巴第血液学网络（REL）的多中心研究。
Am J Hematol. 2019 Nov;94(11):1193-1199. doi: 10.1002/ajh.25600. Epub 2019 Sep 9.
10
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.硼替佐米治疗血液系统恶性肿瘤：15 年后。
Drugs R D. 2019 Jun;19(2):73-92. doi: 10.1007/s40268-019-0269-9.

引用本文的文献

1
Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression.仅表达λ轻链单克隆副蛋白的淋巴浆细胞淋巴瘤
Eur J Case Rep Intern Med. 2022 Feb 11;9(2):003106. doi: 10.12890/2022_003106. eCollection 2022.
2
Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.硼替佐米通过抑制前列腺癌细胞中的 Wnt/β-连环蛋白信号通路增强米托蒽醌的抗肿瘤活性。
BMC Cancer. 2021 Oct 13;21(1):1101. doi: 10.1186/s12885-021-08841-1.

本文引用的文献

1
What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness.未经治疗的华氏巨球蛋白血症最适宜的治疗方案是什么？——利妥昔单抗与半量CHOP疗法的最新分析及成本效益分析
Blood Res. 2019 Jun;54(2):153-156. doi: 10.5045/br.2019.54.2.153. Epub 2019 Jun 25.
2
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion.伴有 6q 缺失的侵袭性华氏巨球蛋白血症的基因表达谱特征。
Biomed Res Int. 2018 Oct 4;2018:6728128. doi: 10.1155/2018/6728128. eCollection 2018.
3
Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience.
韩国淋巴浆细胞淋巴瘤患者（包括非IgM型）的临床特征和生存结局：单中心经验
Blood Res. 2018 Sep;53(3):189-197. doi: 10.5045/br.2018.53.3.189. Epub 2018 Sep 28.
4
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.原发性治疗联合方案及维持用利妥昔单抗治疗巨球蛋白血症的反应和生存情况。
Br J Haematol. 2018 Apr;181(1):77-85. doi: 10.1111/bjh.15148. Epub 2018 Feb 22.
5
Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.伴有非IgM副蛋白的淋巴浆细胞淋巴瘤表现出临床和病理异质性，且可能存在MYD88 L265P突变。
Am J Clin Pathol. 2016 Jun;145(6):843-51. doi: 10.1093/ajcp/aqw072. Epub 2016 Jun 21.
6
Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.伴有单克隆IgG或IgA副蛋白表达的淋巴浆细胞淋巴瘤患者的临床病理特征及预后
Leuk Lymphoma. 2016 May;57(5):1104-13. doi: 10.3109/10428194.2015.1096357. Epub 2015 Dec 23.
7
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.瓦尔登斯特伦巨球蛋白血症中的 MYD88 L265P 体细胞突变。
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
8
Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy.硼替佐米与地塞米松联合治疗成功治愈免疫球蛋白D型骨髓瘤。
Intern Med. 2011;50(21):2653-7. doi: 10.2169/internalmedicine.50.5977. Epub 2011 Nov 1.
9
Report from the Sixth International Workshop on Waldenström's Macroglobulinemia.第六届瓦尔登斯特伦巨球蛋白血症国际研讨会报告
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):68-73. doi: 10.3816/CLML.2011.n.010.
10
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.硼替佐米、地塞米松和利妥昔单抗用于华氏巨球蛋白血症的初始治疗：WMCTG 05-180临床试验
J Clin Oncol. 2009 Aug 10;27(23):3830-5. doi: 10.1200/JCO.2008.20.4677. Epub 2009 Jun 8.